David Ebersman Joins Ironwood Board of Directors

David Ebersman Joins Ironwood Board of Directors

- Facebook CFO and Former Genentech CFO -



CAMBRIDGE, Mass., Sept. 14 /PRNewswire/ -- Ironwood Pharmaceuticals, Inc.
today announced that David Ebersman has joined the Company's Board of
Directors. Mr. Ebersman is the chief financial officer of Facebook. He served
at Genentech from 1994-2009 in a number of senior positions, including
executive vice president and chief financial officer, senior vice president of
product operations, vice president of product development, and project team
leader for Avastin((R)), Genentech's breakthrough cancer therapy. 

(Logo:  http://www.newscom.com/cgi-bin/prnh/20081006/NEM080ALOGO )

"We are thrilled to have David join our board. He is owner-oriented,
exceptionally strategic, and committed to fostering an environment with a high
degree of integrity. He also brings broad industry experience that will enrich
our Board deliberations," said Peter Hecht, CEO of Ironwood.

"I share the Ironwood team's passion for delivering important new medicines to
patients," said Mr. Ebersman. "I am excited to contribute to Ironwood's
efforts to build a great and enduring business."

Mr. Ebersman has an A.B. in economics and international relations from Brown
University and is a fellow in the Henry Crown Fellowship Program.

About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (www.ironwoodpharma.com) is an entrepreneurial
pharmaceutical company dedicated to the art and science of great drugmaking.
Linaclotide, the Company's first-in-class compound, is being evaluated in a
confirmatory Phase 3 program for the treatment of irritable bowel syndrome
with constipation (IBS-C) and chronic constipation. Ironwood also has a
growing pipeline of additional drug candidates in earlier stages of
development. Ironwood has raised $306 million in private equity financing and
is located in Cambridge, Massachusetts.

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.